ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NSRX vs SCYX // RSI-14 & 200D SMA MOMENTUM

Nasus Pharma Ltd. (NYSE) VS. SCYNEXIS Inc. (NASDAQ) • 15-METRIC TALLY: NSRX 4 — SCYX 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: NSRX
rsi-technicals
38.3
rsi-technicals
37.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NSRX VS. SCYX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NSRX SCYX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -13.20% -13.76% +0.56 NSRX /fcf-yield <GO>
Operating Margin -0.40% -60.00% +59.60 NSRX /operating-margins <GO>
Net Profit Margin -0.50% -41.80% +41.30 NSRX /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 SCYX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 38.3 37.7 +0.58 NSRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $37.4M $38.4M -$1.0M SCYX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NSRX REV SCYX REV NSRX GROSS % SCYX GROSS % NSRX FCF SCYX FCF
FY 2025 $1.24B $20.6M — — -$4.9M -$5.3M
FY 2024 $0 $3.7M — — -$665.0K -$24.0M
FY 2023 $0 $140.1M — — -$1.0M $60.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NSRX // BETA —
SCYX // BETA —